Gap analyses are most effective when they combine regulatory rigor with operational realism. ObelysQ delivers independent gap analyses that go beyond theoretical compliance, focusing on how quality systems function in practice. We benchmark current-state processes against applicable regulations and industry best practices, identify true risk drivers, and provide actionable roadmaps that enable organizations to move efficiently from “where they are” to “where they need to be.”
ObelysQ gave us a clear, honest assessment of where our quality system stood and what truly mattered from a regulatory and business perspective. Their gap analysis was practical, prioritized, and directly actionable—exactly what we needed ahead of a major partnership.
Head of Quality, Mid-Sized Pharmaceutical Company
ObelysQ plans and manages gap analyses using a structured, risk-based methodology tailored to the organization’s size, development stage, and regulatory exposure. We start by defining the scope and objectives with senior stakeholders, focusing on what truly matters for inspections, due diligence, or operational scaling. Our assessments combine document review, process walkthroughs, and targeted interviews to understand how quality systems are designed, implemented, and used in practice. Findings are evaluated not only against regulatory requirements but also in terms of business impact and sustainability. We then translate gaps into a prioritized, pragmatic remediation roadmap, clearly distinguishing between immediate risk mitigation actions and longer-term system improvements. Throughout the process, we work collaboratively with client teams to ensure alignment, ownership, and realistic implementation.
Case Study
Overview: A mid-sized pharmaceutical company preparing for a strategic partnership with a global pharma leader needed to demonstrate a robust, inspection-ready Quality Management System. To meet due diligence expectations, the company engaged ObelysQ to perform a comprehensive QMS gap analysis.
Challenge: The QMS had evolved organically over time and had never been systematically assessed against current GxP regulatory requirements. Key issues included fragmented procedures, unclear ownership of quality processes, and missing or weak documentation in critical areas such as CAPA management, training, and change control. The company required a fast yet thorough assessment and a clear, credible remediation roadmap.
Results: ObelysQ conducted an end-to-end gap analysis, benchmarking the QMS against regulatory requirements and recognized best practices. Critical gaps were identified, risks were prioritized, and a phased, pragmatic remediation plan was delivered. Within six months, the company had a streamlined, inspection-ready QMS and successfully passed partner due diligence, enabling progression of the strategic collaboration.
Overview: Following rapid growth and the launch of multiple clinical programs, a biotech recognized that its existing QMS was no longer fit for its expanded scope and complexity. ObelysQ was engaged to perform a deep QMS gap analysis and support the design of a scalable quality framework.
Challenge: The organization had transitioned quickly from early research into late-phase clinical development without establishing the necessary quality infrastructure. Processes varied across departments, document control was insufficient to support audits, and no formal risk management framework was in place. The biotech needed expert guidance to ensure regulatory compliance while enabling continued growth.
Results: ObelysQ performed a comprehensive gap analysis aligned with the company’s development strategy and regulatory footprint. Core quality processes were restructured, risk-based oversight was implemented, and staff were trained on the updated QMS. Within months, the biotech achieved a scalable, robust quality system capable of supporting current operations and future expansion.
Overview: A small biotech approaching its first Health Authority inspection required assurance that its quality systems and clinical oversight processes were inspection-ready.
Challenge: With limited internal quality resources, the company lacked visibility into its true compliance status and potential inspection risks. Documentation was in place but inconsistently applied, and roles and responsibilities were not clearly defined.
Results: ObelysQ conducted a targeted, risk-based gap analysis focusing on inspection-critical processes. High-risk gaps were identified and translated into immediate corrective actions and longer-term improvements. The company entered the inspection period with clarity, confidence, and a defensible quality framework.
Trusted by industry leaders
